Meta-Analysis Confirms DermoElectroPoration Enhances Exosome Delivery in Regenerative Aesthetics
Peer-Reviewed Meta-Analysis Confirms DermoElectroPoration Significantly Enhances Exosome Delivery in Regenerative Aesthetics
Study of Nearly 1,900 Patients Demonstrates Superior, Needle-Free Outcomes Across Multiple Aesthetic and Medical Applications
ATLANTA, GA – December 12, 2025 — A newly published systematic review and meta-analysis in the Journal of Surgery confirms that DermoElectroPoration (DEP) significantly enhances the delivery and clinical effectiveness of human placental mesenchymal stem cell–derived exosomes (hpMSC-exosomes) across a wide range of regenerative aesthetic, dermatologic, and surgical applications.
The peer-reviewed analysis evaluated 28 human clinical studies involving 1,847 patients, along with an additional 50-patient clinical series, making it one of the most comprehensive reviews to date examining DermoElectroPoration-assisted exosome delivery.
Across all indications studied, DEP-enabled delivery produced approximately 85% greater clinical improvement compared to topical application alone (pooled effect size 2.34; p < 0.001), while maintaining an excellent safety profile. No serious adverse events were reported.
“The fields of cellular medicine, regenerative and stem cell therapies continue to grow exponentially. Several methods exist for administering macromolecules to the skin. Our study shows the ability to gain absorption into the dermis topically without the need for needles or any other instrument or device, with no discomfort to our patients. This concept of predictive permeation without needles, pain or downtime is a tremendous addition to our armamentarium for treating multiple issues such as aging skin, acne, alopecia, wounds and scars,” said Greg Chernoff, MD, lead author of the study.
The analysis demonstrated statistically significant improvements across skin rejuvenation, acne, hair restoration, wound healing, and scar therapy. DEP consistently outperformed topical delivery and matched or exceeded invasive alternatives, while avoiding the pain, downtime, and variability commonly associated with injections or micro needling.
DermoElectroPoration utilizes brief, controlled electrical pulses to create temporary microchannels in the skin, enabling efficient transdermal delivery of large bioactive molecules such as exosomes. This non-invasive approach addresses one of the primary limitations of regenerative therapies: reliable, controlled dermal penetration without needles.
The authors conclude that DermoElectroPoration-enhanced exosome delivery represents a next-generation regenerative platform with broad clinical potential. Further large-scale randomized trials and standardized treatment protocols are anticipated to support widespread clinical adoption.
About DEP Medical, Inc.
DEP Medical, Inc. is a U.S.-based medical technology company advancing needle-free regenerative and aesthetic treatments through its proprietary, FDA-cleared DermoElectroPoration (DEP) Platform. The DEP Platform enables controlled transdermal delivery of bioactive compounds into the dermis without needles, pain, or downtime—an approach the company refers to as Predictive Permeation
. DEP Medical supports physicians and medical practices with clinically validated non-invasive solutions across aesthetic and regenerative applications.
Company Information
Company Name – DEP Medical, Inc
Contact Number – 772-634-6771
Email Id – info@depmedical.com
Website – www.depmedical.com
The post Meta-Analysis Confirms DermoElectroPoration Enhances Exosome Delivery in Regenerative Aesthetics first appeared on PR Business News Wire.
